Showing results (81-90 of 103) with videos related to
Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 StudyMaurizio Martelli, Luca Ceriani, Emanuele Zucca, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2016
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic LeukemiaMatthew D Blunt, Stefan Koehrer, Rachel C Dobson, et al.Blood|May 10, 2015
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse modelMatthew D Blunt, Matthew J Carter, Marta Larrayoz, et al.BMJ (Clinical Research Ed.)|September 18, 2021
Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort studyJulia Hippisley-Cox, Carol Ac Coupland, Nisha Mehta, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2019
Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid TumorsTimothy A Yap, Jane N Winter, Lisa Giulino-Roth, et al.Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2014
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerizationAnn L White, Lang Dou, H T Claude Chan, et al.Cancer Immunology Research|September 26, 2025
A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for ImmunotherapyKirstie L S Cleary, Monika Semmrich, Linda Martensson, et al.Leukemia|December 18, 2019
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hitFrancesco Cucco, Sharon Barrans, Chulin Sha, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2023
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-UpAndrew J Davies, Sharon Barrans, Louise Stanton, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to TherapyChulin Sha, Sharon Barrans, Francesco Cucco, et al.Pageof 11